Novel Technology for Intervening in Non-Compressible Haemorrhage

Overview

Defence Medical Services (DMS) and UK Research and Innovation (UKRI), through the Defence and Security Accelerator (DASA), are seeking innovative solutions to tackle Non-Compressible Haemorrhage (NCH) — a leading cause of preventable death in both combat and civilian trauma. Despite advances in casualty care, individuals with significant NCH often die before reaching surgical treatment. This competition aims to accelerate development of novel, life-saving technologies that can be applied in both military and civilian emergency care.

Scope

Projects should focus on developing and advancing novel interventions that can rapidly control or mitigate NCH in pre-hospital environments. Solutions should demonstrate strong potential for translation from early research stages (TRL 2–4) toward higher readiness levels for field deployment.

Key themes and topics

• New technologies for bleeding control in torso or junctional regions
• Portable or field-deployable haemorrhage intervention devices
• Innovative biomaterials or mechanisms to stabilise internal bleeding
• Dual-use medical technologies for both military and civilian trauma care

Project duration

Up to 48 months.
Target contract start date: April 2026.

Award value

Total funding available: up to £1.5 million (excluding VAT).

Funding rates

Projects starting between TRL 2–4 will receive funding through DASA’s standard contract model, based on eligible costs and value for money.

Eligibility criteria

• Open to UK and international organisations with capability to develop novel NCH interventions.
• Projects must align with DASA’s pre-sift and mandatory assessment criteria.
• Proposals must be submitted via the DASA Online Submission Service (registration required).
• Classified information above Official cannot be submitted.

Key dates

• Feedback release: 9 January 2026
• Target contract start: April 2026